Pernicious Anemia

Words: 4443
Pages: 18

Chapter-1
INTRODUCTION

Introduction Anemia is a hematological disorder characterized by decrease in amount of RBCs and hemoglobin in blood (Stedman, 2006). It is one of the unrecognized and untreated situations (Smith, 2010). As anemia progresses, symptoms like excessive thirst, confusion and feeling of pass out is observed (Janz et al., 2013). Anemia affects the people of all ages, but people at greater risk are elderly, young women of childbearing age, and infants. The condition may be develop as a result of various disease. It is not a disease itself but a most widespread disorder of blood that affects the people of all ages. (Benoist et al, 2008). The anemia contributes
…show more content…
This pain is called a "sickle cell crisis", and often affects the bones, lungs, abdomen, and joints. Pernicious anemia Pernicious anemia is a condition in which the body can't make enough healthy red blood cells because it doesn't have enough vitamin B12 (a nutrient found in certain foods). People who have pernicious anemia can't absorb enough vitamin B12 due to a lack of intrinsic factor (a protein made in the stomach). However, other conditions and factors can also cause vitamin B12 deficiency.
Causes
A lack of intrinsic factor is a common cause of pernicious anemia as the body can't absorb enough vitamin B12. Some pernicious anemia occurs because the body's small intestine can't properly absorbvitamin B12 which may be due to the wrong bacteria in the small intestines; certain diseases that interfere with vitamin B12 absorption; certain medicines; surgical removal of part of the small intestine; and tapeworm infection. Sometimes people develop pernicious anemia because they don't get enough vitamin B12 in their diets.

Signs and
…show more content…
It is demonstrated herein that mechanisms in addition to the classical macrophage Fcγ receptor (FcγR) and/or complement-mediated hemolysis may be contributing to the development and/or persistence of anemia. The efficacy of intravenous immunoglobulin (IVIg) therapy varies in relation to the mechanism of anemia in mice with FcγR-mediated anemia being highly related to IVIg responsiveness. Monoclonal RBC-specific antibodies can ameliorate thrombocytopenia in a murine model of passive immune thrombocytopenia (ITP) analogous to the use of anti-D in ITP